Patents by Inventor Linghang Zhuang

Linghang Zhuang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20240124447
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: May 18, 2023
    Publication date: April 18, 2024
    Applicant: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG
  • Inhibitors of the menin-MLL interaction
    Patent number: 11739085
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: August 29, 2023
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20230174541
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 8, 2023
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Fused tricyclic heterocycle compounds and therapeutic uses thereof
    Patent number: 11535633
    Abstract: This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: December 27, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Dong Liu, Lei Chen, Linghang Zhuang, Puhui Li, Xinzhu Zhang, Chunying Song, Matthew Miller, Qiyue Hu, Yuna Yan, Feng He, Weikang Tao
  • Dihydropyrrolopyridine inhibitors of ROR-gamma
    Patent number: 11535614
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 27, 2022
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Inhibitors of the menin-MLL interaction
    Patent number: 11479557
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • AZOLE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220213086
    Abstract: This application discloses azole compounds of formula (I) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, as well as synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: December 24, 2021
    Publication date: July 7, 2022
    Inventors: Hongbin Li, Jian Liu, Bin Cao, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • ALKYNE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220177446
    Abstract: This application discloses alkyne compounds of formula (I) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, and synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Inventors: Hongbin Li, Bin Cao, Jian Liu, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • CD73 inhibitors and therapeutic uses thereof
    Patent number: 11332492
    Abstract: This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 17, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jian Liu, Heping Wu, Linghang Zhuang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • IRAK INHIBITORS, PREPARATION METHOD AND MEDICINAL USES THEREOF
    Publication number: 20220144842
    Abstract: This application discloses compounds of formula (I) and (I?) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, and synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 12, 2022
    Inventors: Hongbin Li, Bin Cao, Jian Liu, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF
    Publication number: 20220135539
    Abstract: This application discloses RAF inhibitors of the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of various disorders related to the excessive RAF activity, including cancers.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 5, 2022
    Inventors: Peng Zhao, Heping Wu, Linghang Zhuang, Yu Zhou, Suxing Liu, Jian Liu
  • TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220056044
    Abstract: Compounds of formula (I) useful as agonists of stimulator of interferon genes (STING), the preparation method therefor, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of STING-mediated diseases or disorders are disclosed.
    Type: Application
    Filed: December 14, 2019
    Publication date: February 24, 2022
    Inventors: Dong Liu, Puhui Li, Linghang Zhuang, Fengqi Zhang, Lei Chen, Xinzhu Zhang, Chunying Song, Suxing Liu, Matthew Miller, Qiyue Hu, Yuna Yan, Jing Li, Feng He, Weikang Tao
  • ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220009909
    Abstract: Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthritis and/or rheumatoid arthritis, are disclosed.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 13, 2022
    Inventors: Dong Liu, Peng Zhao, Jian Liu, Linghang Zhuang, Xinzhu Zhang, Chunying Song, Suxing Liu
  • TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220009910
    Abstract: This application discloses Tyk-2 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, method of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with Tyk-2 activity, such as autoimmune diseases and cancers.
    Type: Application
    Filed: July 10, 2021
    Publication date: January 13, 2022
    Inventors: Linghang Zhuang, Jian Liu, Yinfa Yan, Puhui Li, Yu Zhou, Suxing Liu
  • TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF
    Publication number: 20220002267
    Abstract: Compounds of formula (I) useful as tyrosine kinase 2 (Tyk2) inhibitors, pharmaceutical compositions containing these compounds, methods of using the pharmaceutical compositions in the treatment of various disorders related to the regulation of Tyk2 activity, and methods of preparing these compounds are disclosed.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 6, 2022
    Inventors: Linghang Zhuang, Jian Liu, Heping Wu, Puhui Li, Yu Zhou, Suxing Liu
  • MODULATORS OF ROR-GAMMA
    Publication number: 20210300869
    Abstract: Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Such derivatives include e.g., those having the Formula II. as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: September 25, 2020
    Publication date: September 30, 2021
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Linghang Zhuang
  • FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF
    Publication number: 20210300944
    Abstract: This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 30, 2021
    Inventors: Dong Liu, Lei Chen, Linghang Zhuang, Puhui Li, Xinzhu Zhang, Chunying Song, Matthew Miller, Qiyue Hu, Yuna Yan, Feng He, Weikang Tao
  • CD73 INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210253621
    Abstract: This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.
    Type: Application
    Filed: August 28, 2019
    Publication date: August 19, 2021
    Inventors: Jian Liu, Heping Wu, Linghang Zhuang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
    Publication number: 20210238174
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: September 9, 2020
    Publication date: August 5, 2021
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20210179611
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: August 11, 2020
    Publication date: June 17, 2021
    Applicant: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG